# Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

> **NCT03736889** · PHASE2 · RECRUITING · sponsor: **BeiGene** · enrollment: 200 (estimated)

## Conditions studied

- MSI-H/dMMR Solid Tumors

## Interventions

- **DRUG:** Tislelizumab (BGB-A317)

## Key facts

- **NCT ID:** NCT03736889
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-09-19
- **Primary completion:** 2026-11
- **Final completion:** 2027-09
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03736889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03736889, "Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03736889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*